Bifocal Lenses In Nearsighted Kids

Refractive Errors Clinical Trial

— BLINK  

Official title:

Soft Bifocal Contact Lens Myopia Control

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02255474
• Other study ID #: 2014H0231
• Secondary ID: U10EY023208
• Status: Completed
• Phase: N/A
• Start date: September 22, 2014
• Est. completion date: June 24, 2019

Study information

• Verified date: February 2021
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the use of two different bifocal contact lens add powers to prevent further nearsighted progression in children ages 7 to 11 years old. It is theorized that the profile of the bifocal lenses will decrease the amount of change in nearsightedness that the children experience.

Description:

The primary goal of this project is to determine whether a commercially available soft bifocal contact lens with a distance-center design can slow myopia progression in children. Using soft bifocal contact lenses to manipulate the peripheral optics of the eye is a novel use for a standard contact lens that may keep children from becoming as nearsighted as they would otherwise. Secondary goals are to determine whether the amount of myopic defocus imposed on the peripheral retina by soft bifocal contact lenses is associated in a dose-dependent manner with slowed myopic progression and to determine whether peripheral myopic blur acts to slow eye growth locally or globally. These important pieces of information will enable investigators to learn about the role of peripheral optics for regulating eye growth, which could ultimately lead to optimization of optical signals to slow myopia progression. Ultimately, the information could be used to design optical devices to prevent the onset of myopia in young children. Slowing myopia progression or eventually preventing myopia onset could potentially affect approximately 60 million children in the United States alone. While the consequences of myopia are rarely sight-threatening, the quality of life for myopic patients is negatively affected and the health care costs to treat myopia are astronomical (approximately $4.6 billion in 1990). The National Eye Institute recognizes the need to "evaluate the efficacy of potential treatments for delaying the onset or for slowing the progression of myopia, such as lenses that alter peripheral defocus." Using a common treatment of myopia (contact lenses) to potentially slow myopia progression and to learn about optical signals that regulate eye growth is a very novel approach to solving a problem that affects a large proportion of people in the United States.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 294
• Est. completion date: June 24, 2019
• Est. primary completion date: June 24, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 11 Years

Eligibility

Inclusion Criteria:

• 7 to 11 years, inclusive, at baseline examination
• -0.75 to -5.00 D, inclusive, spherical component, cycloplegic autorefraction
• =1.00 DC, cycloplegic autorefraction
• = 2.00 D difference between the sphere components of the two eyes (anisometropia), cycloplegic autorefraction
• 0.1 logMAR or better best-corrected visual acuity in each eye
• 0.1 logMAR or better visual acuity OU distance and near with a +2.50 D add contact lens
• +2.50 D add lens provides adequate fit with respect to movement and centration

Exclusion Criteria:

• Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.)
• Systemic disease that may affect vision, vision development, or contact lens wear (eg, diabetes, Down syndrome, etc.)
• Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL spectacle wear (longer than 1 month of wear)
• Previous or current participation in myopia control studies
• Chronic use of medications that may affect immunity, such as oral or ophthalmic corticosteroids for ocular or systemic diseases
• Issues that may interfere with the ability to participate over the next 3 years

Related Conditions & MeSH terms

• Refractive Errors

Intervention

Device:
• Biofinity Multifocal D +1.50 add
This is a monthly disposable contact lens commercially available from CooperVision
• Biofinity Multifocal D +2.50 add
This is a monthly disposable contact lens commercially available from CooperVision
• Biofinity
This is a monthly disposable spherical contact lens commercially available from CooperVision

Locations

Country	Name	City	State
United States	Ohio State University College of Optometry	Columbus	Ohio
United States	University of Houston College of Optometry	Houston	Texas

Sponsors (3)

Lead Sponsor	Collaborator
Ohio State University	National Eye Institute (NEI), University of Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Refractive Error Progression	Refractive error, as measured by cycloplegic autorefraction in both eyes, will be measured yearly to assess the difference in progression between the two soft bifocal treatment lenses (+1.50 D add and +2.50 D add) and the control group (soft spherical contact lenses).	3 years
Secondary	Ocular Shape Change and Eye Growth	The outcome of interest is the change in ocular shape and measured by the change in peripheral refractive error in the right eye. The change in peripheral refractive error will be compared among the two treatment groups and the control group to determine whether peripheral defocus changes the shape of the eye globally (across the whole eye) or locally (specific to the region of the eye affected by the defocus).	3 years
Secondary	Association of Peripheral Defocus to Myopic Progression	Peripheral defocus will be measured in 10 areas (Nasal and temporal zones at 20, 30, and 40 degrees, and superior and inferior zones at 20 and 30 degrees) and analyzed for its relation to myopia progression (as measured by cycloplegic autorefraction in the right eye only).	3 years
Secondary	Axial Length Progression	Axial length progression, as measured by Lenstar in both eyes, will be measured yearly to assess the difference in progression between the two soft bifocal treatment lenses (+1.50 D add and +2.50 D add) and the control group (soft spherical contact lenses).	3 years